Pharmaceutical Innovation Flourishes: Multiple Novel Drugs Enter Clinical Trials Globally

　　【Pharmaceutical Network Industry DynamicsIn recent years, against the backdrop of intensifying competition in the pharmaceutical industry, there has been a surge in enthusiasm for new drug development both in China and internationally. As numerous pharmaceutical companies continue to increase their investment in research and development, steadily advancing clinical research for innovative drugs, an increasing number of innovative drug projects are now accelerating through clinical trials.
 

Gannex Pharma Submits IND Application for ASC10 to FDA
 

On July 6, Ascletis Pharma announced on the Hong Kong Stock Exchange that after completing the pre-Investigational New Drug (IND) consultation meeting, it has submitted a new drug clinical trial application to the U.S. Food and Drug Administration (FDA) for its oral COVID-19 candidate drug, the RNA-dependent RNA polymerase (RdRp) inhibitor ASC10. ASC10 is an oral small-molecule candidate drug targeting the RdRp of the novel coronavirus and is an oral dual prodrug of the antiviral nucleoside analog ASC10-A.
 

Fosun Pharma's FS-1502 Receives Drug Clinical Trial Approval
 

On July 5, Fosun Pharma announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., had received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial of FS-1502 (i.e., Recombinant Humanized HER2 Monoclonal Antibody-Monomethyl Auristatin F Conjugate for Injection) in combination with Serplulimab and/or chemotherapy for the treatment of patients with HER2-expressing advanced gastric cancer. Fosun Pharmaceutical plans to initiate a Phase II clinical trial of this treatment regimen within mainland China (excluding Hong Kong, Macao, and Taiwan) once conditions are met.
 

JWATM204 Phase 1 Clinical Study Initiated by WuXi AppTec
 

On July 4, WuXi JiaWei announced the initiation of a Phase 1 clinical study for JWATM204, an innovative cellular immunotherapy drug for the treatment of advanced hepatocellular carcinoma. JWATM204 is an immune T-cell therapy targeting GPC-3. Notably, this clinical study marks the first-in-human trial for this treatment and represents a significant advancement in WuXi JiaWei's exploration of immune T-cell therapies for solid tumors.
 

Eli Lilly's GLP-1R/GIPR Dual Agonist Initiates Phase III Clinical Trial
 

On July 4, Eli Lilly's GLP-1R/GIPR dual agonist Tirzepatide initiated a randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial, codenamed SURMOUNT-OSA. This study aims to evaluate the efficacy and safety of once-weekly Tirzepatide administration in treating patients with obstructive sleep apnea and obesity (both those receiving PAP therapy and those unwilling or unable to use PAP therapy).
 

MSD will launch an international multi-center (including China) Phase 3 clinical trial
 

On July 4, the Chinese Drug Clinical Trial Registration and Information Disclosure Platform showed that MSD registered an international multicenter (including China) Phase 3 clinical trial to evaluate the safety and efficacy of MK-7684A in combination with concurrent chemoradiotherapy followed by MK-7684A in patients with unresectable locally advanced, Stage III non-small cell lung cancer. Public information indicates that MK-7684A is a compound preparation consisting of the anti-TIGIT antibody vibostolimab and the PD-1 inhibitor pembrolizumab, currently in Phase 3 clinical trials globally.
 

　　Conclusion
 

Although the development of the innovative drug industry is currently in full swing, it is important to note that the cost of new drug research and development is enormous, and the risks are also very high. In recent years, while enthusiasm for new drug R&D has been high both in China and abroad, a large number of new drugs have failed between Phase III and the marketing stage, resulting in projects costing hundreds of millions of dollars being written off, which has become commonplace. Therefore, pharmaceutical companies need to clearly recognize that the R&D of innovative drugs is not a smooth path, but rather a situation where risks and benefits coexist, and they must be prepared for a protracted battle.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.